Highlights of the development in personalized treatment of patients with diffuse large B-cell lymphoma:reports in the 54 ASH annual meeting
10.3760/cma.j.issn.1009-9921.2013.02.003
- VernacularTitle:弥漫大B细胞淋巴瘤个体化治疗重要研究进展:第54届美国血液学会年会报道
- Author:
Yanyan LIU
;
Yufu LI
;
Shujun YANG
;
Yongping SONG
- Publication Type:Journal Article
- Keywords:
Diffuse large B-cell lymphoma;
Personalized treatment;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2013;22(2):71-73
- CountryChina
- Language:Chinese
-
Abstract:
The outcome of diffuse.Large B-cell lymphoma (DLBCL) has been improved in the last decades and will be raised further with the development of novel agents in the future.Personalized treatment for DLBCL is based on its molecular heterogeneity.Except for concurrent translocation of myc and bcl-2,neither clinical nor biological factor is sufficiently available to be used to guide the deviation of R-CHOP therapy in DLBCL.Gene expression profiling and whole genomic analytic techniques are expected to be important approaches at present to determine personalized treatment for DLBCL.The advance in the field being reported by Laurie H.Sehn from University of British Columbia in the 54 ASH meeting was summarized in the paper.
